News search

The results, published in the European Heart Journal and presented at the European Society of Cardiology Congress, opens the way to new therapies for patients with genetic heart diseases

Scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), together with cardiologists from Hospital Universitario Puerta de Hierro and the Spanish cardiovascular disease research network (CIBERCV), report that the new discovery makes it possible to identify high-risk patients early and refer them sooner to specialized heart failure units

REBOOT trial, coordinated by the CNIC, shows that treatment with beta-blockers provides no benefit to patients who experience an uncomplicated heart attack that leaves the contractile function of the heart intact.

The European Society of Cardiology is holding its annual congress in Madrid from August 29 to September 1

Dr. Claudia Monaco, Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK

A new study led by the CNIC has identified imidazole propionate (ImP), a metabolite produced by gut bacteria, as a driver of atherosclerosis— as a driver of atherosclerosis, the disease behind most heart attacks and strokes

CNIC researchers have uncovered the evolutionary logic of the OxPhos system—the cell’s “engine”—and developed a tool to detect mutations that cause mitochondrial disease